The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial
Clin Nutr, . 2020 Nov 7;S0261-5614(20)30609-9. doi: 10.1016/j.clnu.2020.11.005
Abolfazl Zendehdel 1, Mohsen Ansari 2, Farnaz Khatami 3, Shapour Mansoursamaei 4, Hossein Dialameh 5
This list is automatically updated
Cancer - Prostate category listing has
Items in both categories Cancer - Prostate and Intervention are listed here:
- 2.5 X reduced risk of cancer in 70 year-olds by a small amount of Vitamin D, Omega-3 and exercise – RCT April 2022
- Prostate Cancer PSA reduced by 60 ng of Vitamin D, Vitamin B complex, Omega-3, Curcumin and diet – June 2021
- BPH (PSA) decreased by Vitamin D (50,000 IU bi-weekly) – RCT Nov 2020
- Prostate Cancer might be treated by 4,000 IU of vitamin D and aspirin – RCT 2021
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
- Prostate cancer reduced when 4000 IU vitamin D was added– Hollis RCT April 2015
- Low risk Prostate Cancer decreased with 4,000 IU of vitamin D – July 2012
Background and aims: Inflammation and proliferation are the cause of benign prostatic hyperplasia (BPH) and are the key components of its mechanism of action. In this study we sought to determine the role of 25-hydroxyvitamin D in BPH, because of its anti-inflammatory activities, and its effect on prostate volume and BPH symptoms.
Methods: This randomized clinical trial (RCT) was conducted on 108 participants >50 years of age who had either asymptomatic or mild BPH symptoms according to the International Prostate Symptom Score (IPSS) questionnaire. Patients were randomly divided into two groups, intervention and control. The intervention group received 50 000 units of vitamin D3 and the control group received a placebo every two weeks for six months. Prostate ultrasound, routine clinical examinations, toucher rectal (TR), and laboratory tests were performed for all patients. After six months, the patients underwent another ultrasound evaluation, measurement of prostate-specific antigen (PSA) levels and completed the IPSS. Results of the evaluations before and after the intervention were compared between the groups using the chi-square, t-test, and logistic regression analysis. Repeated measure analysis was used to evaluate the effect of vitamin D intervention on the changes in the IPSS score.
Results: The mean age of the participants was 56 ± 9 years. In the control group, the mean prostate volume was higher compared to the intervention group (p < 0.001). The control group had a higher mean PSA level than the intervention group (p < 0.001). Although the IPSS score decreased over time in both groups, analysis of variance showed that the amount of change or decrease in IPSS score in the intervention group was significantly more than the control group (p < 0.001).
Conclusions: The results of our study support the effect of vitamin D in reducing prostate volume and PSA levels, and in improving BPH symptoms. Further studies are needed to confirm these findings to verify the use of vitamin D as a treatment for BPH.
|2794 visitors, last modified 06 Apr, 2022,